Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor‐promoted inflammatory responses and prostate cancer progression

Abstract Chronic inflammation is one of the definite factors leading to the occurrence and development of tumors, including prostate cancer (PCa). The androgen receptor (AR) pathway is essential for PCa tumorigenesis and inflammatory response. However, little is known about the AR‐regulated NACHT, LRR, and PYD domain‐containing protein 3 (NLRP3) inflammasome pathway in human PCa. In this study, we explored the expression of inflammatory cytokine and AR in high‐grade PCa and observed that NLRP3 inflammasome‐associated genes were upregulated in high‐grade PCa compared with that in low‐grade PCa and benign prostatic hyperplasia and were associated with AR expression. In addition, we identified circAR‐3—a circRNA derived from the AR gene—which is involved in the AR‐regulated inflammatory response and cell proliferation by activating the NLRP3 inflammatory pathway. While circAR‐3 overexpression promoted cell proliferation and the inflammatory response, its depletion induced opposite effects. Mechanistically, we noted that circAR‐3 mediated the acetylation modification of NLRP3 by KAT2B and then promoted NLRP3 inflammasome complex subcellular distribution and assembly. Disturbing NLRP3 acetylation or blocking inflammasome assembly with an inhibitor suppressed the progression of PCa xenograft tumors. Our findings provide the first evidence that targeting NLRP3 acetylation or inflammasome assembly may be effective in inhibiting PCa progression.